Safety and Survival Outcomes of Neoadjuvant Chemoradiotherapy Combined with Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Real-World Analysis (NEO-EC-01) - PubMed
6 hours ago
- #Esophageal cancer
- #Survival outcomes
- #Immunotherapy
- Neoadjuvant chemoradiotherapy (nCRT) combined with immunotherapy (nICRT) shows promise for locally advanced esophageal squamous cell carcinoma (LA-ESCC).
- Multicenter real-world study (NEO-EC-01) evaluated 71 LA-ESCC patients undergoing nICRT followed by esophagectomy.
- Pathological complete response (pCR) rate was 50.7%, and major pathological response (mPR) rate was 77.5%.
- Grade ≥3 adverse events occurred in 35.2% of patients, mainly neutropenia (31.0%) and radiation esophagitis (7.0%).
- Postoperative complications included anastomotic leakage (4.2%) and pneumonia (15.5%).
- 2-year and 3-year overall survival (OS) rates were 81.5% and 70.6%, respectively.
- 2-year and 3-year disease-free survival (DFS) rates were 70.3% and 58.0%, respectively.
- Recurrence patterns: locoregional (16.9%) and distant metastases (32.4%).
- Pathological N stage and elevated platelet-to-lymphocyte ratio (PLR) were independent prognostic factors for OS and DFS.
- Adjuvant therapy improved survival in non-pCR patients (75% vs. 53.3% 2-year OS).